Last reviewed · How we verify
Plasmocid (rhodoquine)
Plasmocid (generic name: rhodoquine) is a rhodoquine drug. It is currently in unknown development.
Plasmocid works by interfering with the parasite's ability to use hemoglobin, ultimately leading to its death.
Plasmocid, also known as rhodoquine, is a small molecule drug in the rhodoquine class. It is used to treat malaria, a disease caused by Plasmodium parasites. The commercial status of Plasmocid is unclear, and it is not known if it is patented or available as a generic. Further information on its approval status, half-life, bioavailability, and generic manufacturers is not available. As a result, key safety considerations and pharmacological details are also unknown.
At a glance
| Generic name | rhodoquine |
|---|---|
| Drug class | rhodoquine |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine the parasite's digestive system is like a car engine that runs on gasoline. Plasmocid is like a special additive that clogs up the engine, preventing it from working properly and causing the parasite to die.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plasmocid CI brief — competitive landscape report
- Plasmocid updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Plasmocid
What is Plasmocid?
How does Plasmocid work?
What is the generic name of Plasmocid?
What drug class is Plasmocid in?
What development phase is Plasmocid in?
Related
- Drug class: All rhodoquine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing